Iffat retweeted
一个 skill，让你做出顶级审美的图表。
我开源的 Lieflat Charts 已经在 GitHub 2k star 啦～它是一套数据可视化与报告生成 skill，可供 Moxt、Claude Code、Codex 等 AI agent 使用。
它由统一的字体、留白、线条和动效建立视觉语法，有60多种图型，覆盖柱、线、面积、直方图等基础图型，还有热力图、小提琴图、环形关系图、桑基图等复杂图型，部分还支持交互。
色彩上，以黑白灰单色为基础，也支持青瓷蓝、椰林绿、编辑红三种色系，后续还会尝试更多丰富配色～
这个skill 的原理是用 html 来做图表，好处很明显，有很丰富的动效，可以无缝衔接到 html 做的 PPT 中。如果需要 PPT 格式，也可以让 agent 转成动图贴进 PPT 里。
使用非常简单，装好后把你的数据或者想要可视化的主题告诉agent，agent 会选择合适的图表类型，自动出图。如果你需要出报告，目前也有报告模式，可以一键产出数据可视化报告。
感谢 @moxt_ai 让我做出这么好看的图表！
#datavisualization #charts #skill #dataviz #html #aidesign
Iffat retweeted
15 weird London AI companies you've probably never heard of
London's AI scene isn't just chatbots and SaaS.
Some genuinely strange stuff happening.
@PrimaMente – building "foundation models for the brain" to study Alzheimer's and Parkinson's.
Hologen – frontier medical AI spinout tied to UCL/King's. Eric Schmidt involved. hologen.ai
@baseimmune – AI-designed vaccines targeting rapidly mutating viruses.
@RecursionPharma / @valence_ai – AI drug discovery platform combining chemistry, biology and machine learning.
@CausalyAI – AI that reads scientific papers and maps biomedical knowledge graphs.
Fractile – building new AI chip architecture. fractile.ai
@mindgard – "red teaming" AI models to find vulnerabilities.
@Limbic_ai – mental health triage AI used in NHS services.
@LindusHealth – clinical trials run with AI infrastructure.
Anima Health – AI triage platform for healthcare providers. animahealth.com
AUAR – robots that build buildings. AI for automated construction. auar.io
@testudoglobal – insurance for the AI economy.
Isomorphic Labs – DeepMind spinout doing AI drug discovery. isomorphiclabs.com
BenevolentAI – one of the earliest AI drug discovery companies. benevolent.com
London AI ecosystem is weirder than people think.
Still mapping more.
Comment any i've missed so far.
londonmaxxxing.com/
Iffat retweeted
Dear followers, this is a fascinating, thought-provoking article on AI and drug discovery. The facts are very interesting. I suspect the pattern that Daphne Koller documents may apply more broadly than just to drug discovery. deepphenotype.substack.com/p…
Iffat retweeted
Alex on why AI + fully autonomous labs will compress drug discovery from five years to two:
"If scientists are armed with agentic infrastructure that has an intelligence that's a multiple of Einstein, they will do science faster, with higher probability, for lower cost, and have greater impact."
"AI coming into the discovery of medicines is one of the biggest unlocks we will see in history because it means we're no longer constrained by our hands or minds. We can identify all n number of hypotheses that could exist, figure out the best experiment to run, and run those 24/7."
"The sheer ability to be more comprehensive in our hypothesis set, and to run experimentation at unprecedented scale, means we're going to speed breakthroughs from timelines that take three to five years to timelines that take less than a couple of years."
Alex Karnal (@alex_karnal) is the most talented bio and healthcare investor I've ever met.
He's spent 20 years in the industry and says 2025 was the single most exciting year he's seen. The start of a once-in-a-lifetime, trillion-dollar revolution in public health.
He explains how few people realize we already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them.
There's a population of people born with a mutation that means their bodies don't produce a protein called PCSK9. Their lifetime risk of cardiovascular disease is 88% lower than yours. Pharma turned that genetic advantage into a drug. It's been approved for years, but the number of people taking it is still vanishingly small.
Partly because high cholesterol is a silent killer. You feel nothing, right up until you have a heart attack. And partly because the health system makes it punishingly hard to stay on a preventive drug like a PCSK9 inhibitor. In other words, the medicine works, but the system around it doesn't.
That's what's starting to change, and in this episode, Alex explains why.
We discuss the "health stack" he believes can add a decade to most lives, why oral GLP-1s are breaking every adoption record in pharma, peptides and citizen pharmacology, and what AI is doing to drug discovery.
I wish I had an "Alex" for every interesting topic. We've been having versions of this conversation for over five years, and every single one is as clear and as useful as this one.
Enjoy!
Timestamps:
0:00 Intro
1:00 The State of Modern Medicine
5:00 Designing the Modern Health Stack
12:17 The GLP-1 Inflection Point
19:18 The Biological Mechanisms of GLP-1
30:36 Overcoming Frictions in Healthcare
34:19 Cardiovascular Disease
44:04 Addressing Alzheimer's
47:04 The Future of Cancer
57:33 Drug Discovery
1:05:25 AI and Scientific Super Intelligence
1:14:40 Citizen Pharmacology and the Peptide Movement
1:18:13 Background and Career Journey
1:31:09 Braidwell's Investment Approach
1:33:30 The Kindest Thing
Iffat retweeted
biotech is the ultimate frontier
- Eli Lilly is on an acquisition spree, funding it entirely off obesity drug profits
- Anthropic runs its own internal drug discovery lab now
- OpenAI put health directly into ChatGPT
- Midjourney pivoted from AI images to a full-body medical scanner
- Roche paid $2.3B for a Phase 1 obesity drug and $750M more on manufacturing
- Nvidia is building a $1B AI drug discovery lab with Lilly
- Colossal is raising at $20-30B to industrialize genetic engineering itself
- Isomorphic Labs raised $2.1B to design drugs with AI, already in human trials
- J&J committed up to $3.5B to turn CAR-T into a simple injection
- argenx spent $2.2B expanding antibody therapies for autoimmune disease
pharma and big AI are converging on frontier bio
Iffat retweeted
🚀 5 new drug-discovery specialist LLMs. SOTA-level performance across 70+ benchmark tasks.
Insilico Medicine has released a series of frontier Specialist Language Models for chemistry and biology, trained through MMAI Gym.
They cover drug safety, potency prediction, chemical synthesis, and biology.
🧬 From general-purpose models to scientific specialists.
Iffat retweeted
you aren't bullish enough on agentic biology.
agentic biology is how we will cure cancer, rapidly build vaccines against superviruses, and enhance the human body beyond its natural limits
and the reason is simple: time compression
the FDA’s standard timeline puts discovery + preclinical work at 3-6 years before a drug even reaches human trials
because the current process is agonizingly slow:
→ specialists spend months designing molecules for one disease target
→ a contract lab takes another 6-8 weeks to make and test each batch
→ scientists analyze what worked
→ start the next batch
but agentic biology massively compresses that loop:
→ Claude designs candidates in 24-48 hours
→ robots physically make and test them
→ results come back in under 3 weeks
→ AI learns from the data and designs a better batch
→ repeat
Adaptyv says one campaign that once required a whole lab for a year can now run from a laptop in a few weeks
clinical trials and approval still take years
but when the discovery loop runs this much faster...
we get far more shots on goal at finding treatments for cancers, rare diseases and viruses that medicine can’t solve today
We raised a $40M Series A to build the automated lab for agentic biology.
Last week, we shared the work we did with @Anthropic: Claude designed proteins, sent them to our automated wet lab, and got real experimental data back.
We believe this is where biology is going: AI agents designing experiments, running them in automated wet labs, learning from the results and iterating.
But AI can only move as fast as the experiments behind it. To use the potential of AI to cure all diseases, we need to build high-throughput wet lab infrastructure: a “biological gigafactory”.
That’s exactly what we’re doing at Adaptyv.
Over the past year we’ve grown our lab throughput by over 5x and onboarded more than 100 customers, ranging from bio AI labs like @chaidiscovery and @boltz_bio to pharmas like @Roche and @novonordisk to dozens and dozens of new startups that use AI to radically speed up drug discovery.
Iffat retweeted
“Once the platform works, biology becomes programmable.”
Demis Hassabis, CEO of Google DeepMind, says AI drug discovery won’t progress gradually.
It will look more like AlphaFold, years of quiet infrastructure work, then a sudden leap where the system can scale across entire disease areas.
Iffat retweeted
“In five years, doing drug design without AI will be like doing science without maths.”
Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents.
You guide them. They search molecular space and return in hours with what would've taken humans weeks.
Iffat retweeted
We've a postdoc opening for our lab at the Broad: Cambridge MA!
Must have experience in toxicology + data science
Work on the wonderful OASIS dataset we are producing... Cell Painting, transcriptomics, proteomics in various liver cell and tissue models!
broad.io/mlcbpostdoc
Iffat retweeted
Now on biorxiv! The JUMP-Cell Painting Consortium’s paper:
“Morphological map of under- and over-expression of genes in human cells”
This is the genetic perturbation portion of the JUMP’s dataset; our chemical perturbation paper will come in a few months
biorxiv.org/content/10.1101/…
Iffat retweeted
The main effect of AI in the biotech industry over the next 5-10 years will be to greatly increase the value of an already scarce resource: senior scientific judgement
when every senior scientist has greater operational leverage (faster hit finding, better lead optimization, agentic execution of experiments, AI aided recruitment of clinical trials, etc.)
--> the key *scientific* decisions in making a drug become even more critical:
- target selection --> already the make or break question for most biotechs, but definitely can't be replaced by AI for the time being
- indication selection for chosen target
- clin dev strategy (which patient pop to enter first, what to choose as control, etc)
Small groups of scientists, armed with computational tooling, a la nimbus, nuvalent, etc. will have an outsized share of drugs developed
Iffat retweeted
🇪🇺🇫🇷It is official! We are expanding 🌍
As @OpenAI announced this week we are opening an office in Paris, as well as Brussels, NYC, Seattle and Singapore!
I 💙🤍❤️ startups in France and across Europe and am so excited to grow our presence and keep building, now even more closely with the amazing founder community here.
👩🍳Keep an eye out and catch me and @kagigz in Paris soon.
Iffat retweeted
1/3
#PhD, tentez de remporter l'un des prix suivants en candidatant à notre concours d'octobre, ouvert aux inscriptions jusqu'au 22 !
1er prix : Bon d’achat FNAC de 100€.
2ème prix : Bon d’achat FNAC de 50€.
3ème prix : Mise en avant du profil par @PhDTalent sur son LinkedIn.
Excited for this huge event!
10ème édition de BIG, notre grand rendez-vous annuel dédié à l'entrepreneuriat ! @Bpifrance
70 000 personnes attendues à l'@Accor_Arena ce 10/10.
Pourquoi avoir choisi le thème du Progrès pour cette édition spéciale ? Je l'ai expliqué à @LaTribune
latribune.fr/supplement/la-t…
So excited to be in Boston for SBI2 conference 2024! Was expecting the weather to be colder than Paris but pleasantly surprised. Also Boston public transport: A+!
Iffat retweeted
Wow! I'm thrilled that our new company SyzOnc was awarded the Grand Prize in the MIT-Royalty Pharma competition!
This cohort of 12 MIT professors represents the best of what science can be when leaders are passionate about making a positive impact on the world.
